German biotech firm CureVac has filed a patent infringement lawsuit against Moderna, alleging that Moderna’s Spikevax COVID-19 vaccine unlawfully uses CureVac’s proprietary mRNA technology related to nucleotide modifications and delivery systems, a legal dispute that could influence future vaccine development and intellectual property frameworks in global pandemic preparedness.
The Legal Battle Over mRNA Intellectual Property in Pandemic Vaccines
CureVac’s lawsuit, filed in multiple jurisdictions including the United States District Court for the District of Massachusetts and the Unified Patent Court in Europe, centers on claims that Moderna’s Spikevax vaccine infringes on CureVac-owned patents covering specific chemical modifications to messenger RNA (mRNA) that enhance stability and reduce innate immune recognition—key innovations that allow synthetic mRNA to evade rapid degradation and excessive inflammation after injection. These modifications, particularly the use of modified nucleosides like pseudouridine, are foundational to the efficacy and safety profile of modern mRNA vaccines. While both companies independently developed their COVID-19 vaccines during the pandemic, CureVac asserts that Moderna’s formulation relies on core patented technologies developed in CureVac’s early mRNA research programs dating back to 2012, long before the emergence of SARS-CoV-2.
In Plain English: The Clinical Takeaway
The lawsuit does not affect the safety, effectiveness, or availability of current Moderna or CureVac vaccines for patients.
mRNA vaccines operate by teaching cells to make a harmless piece of the virus so the immune system learns to fight it—this technology is safe and rigorously tested.
Ongoing legal disputes over patents are common in biotech and typically resolved through licensing or settlements, not by removing vaccines from public use.
Clinical Mechanism and Pandemic Impact of mRNA Vaccine Technology
The mRNA platform used in both Spikevax and CureVac’s investigational candidates delivers synthetic mRNA encoding the SARS-CoV-2 spike protein into host cells via lipid nanoparticles (LNPs). Once inside, the mRNA is translated by ribosomes to produce the antigen, triggering both humoral and cellular immune responses. Key to this process is the avoidance of pathogen-associated molecular pattern (PAMP) recognition by Toll-like receptors (TLRs), which is achieved through nucleoside modifications—specifically, the substitution of uridine with N1-methylpseudouridine (m1Ψ)—a innovation central to CureVac’s patent claims. Clinical data from Moderna’s Phase III COVE trial (N=30,420) showed 94.1% efficacy against symptomatic COVID-19, with a favorable safety profile; serious adverse events were rare and balanced between groups (PMID: 33301246). CureVac’s own second-generation vaccine, CV2CoV, demonstrated 77% efficacy in the pivotal HERALD trial (N=40,000) against variants of concern, though it has not yet received broad regulatory approval (PMID: 35050647).
Moderna Vaccines Vaccine
Geopolitical and Regulatory Implications for Vaccine Access
This litigation unfolds amid ongoing efforts by the WorldHealth Organization (WHO) and regional regulators to strengthen equitable access to pandemic vaccines through technology transfer and voluntary licensing pools. The European Medicines Agency (EMA) has emphasized that intellectual property disputes should not disrupt vaccine supply chains, particularly as updated boosters targeting XBB-lineage variants remain critical for immunocompromised populations in the EU. In the United States, the FDA continues to authorize mRNA boosters under emergency use provisions, with ACIP recommending seasonal updates similar to influenza vaccines. Legal experts note that while patent litigation is routine in pharmaceutical innovation, courts often encourage negotiation—especially when public health is at stake. As of early 2026, both companies continue to supply vaccines through COVAX and bilateral agreements, with no reported disruptions tied to the litigation.
Funding Sources and Potential Conflicts of Interest
The foundational mRNA research underpinning CureVac’s patent portfolio was supported by grants from the German Federal Ministry of Education and Research (BMBF), the European Union’s Horizon 2020 program and private investments from Dievini Hopp BioTech holding. Moderna’s early mRNA work received significant funding from the Defense Advanced Research Projects Agency (DARPA) and the Biomedical Advanced Research and Development Authority (BARDA), particularly during the 2020 pandemic response. Neither company’s current vaccine sales or litigation strategy is directly funded by these original grants; however, transparency disclosures indicate that CureVac’s legal expenses are covered by its corporate reserves, while Moderna has stated it will defend its patents vigorously using existing legal budgets. No external entities are funding litigation on either side, reducing concerns about third-party bias in the legal proceedings.
Moderna Accuses Pfizer Of Copying Its COVID-19 Vaccine Technology
Expert Perspectives on Innovation and Access
“While protecting intellectual property incentivizes innovation, we must ensure that patent thickets do not hinder rapid vaccine adaptation during future pandemics. Licensing frameworks, not litigation, should govern emergency responses.”
Vaccines Vaccine Clinical
“The mRNA modifications at the heart of this dispute are not legal technicalities—they are why these vaccines work safely in millions of people. Undermining that science risks public trust.”
Contraindications & When to Consult a Doctor
This legal dispute does not alter clinical guidance for mRNA COVID-19 vaccines. Contraindications remain limited to known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including polyethylene glycol (PEG) in lipid nanoparticles or the mRNA itself—a condition affecting fewer than 1 in a million doses. Individuals with a history of myocarditis, particularly adolescent males after the second dose, should consult a cardiologist before additional doses, though risk remains low and outcomes are generally favorable with rest and monitoring. Anyone experiencing chest pain, shortness of breath, or palpitations within days of vaccination should seek immediate medical care. For the general public, including pregnant individuals and those with immunocompromising conditions, mRNA vaccines continue to be recommended as safe and effective by WHO, CDC, and EMA, with benefits vastly outweighing risks.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
